about
Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral LeishmaniasisRegulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasisLeishmania eukaryotic initiation factor (LeIF) inhibits parasite growth in murine macrophagesAntimony resistant Leishmania donovani but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF-β in early immune responseImmunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral LeishmaniasisImmunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse modelThe curative effect of fucoidan on visceral leishmaniasis is mediated by activation of MAP kinases through specific protein kinase C isoformsAssociation of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral leishmaniasis.Isobenzofuranone derivatives exhibit antileishmanial effect by inhibiting type II DNA topoisomerase and inducing host response.Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.Identification and functional characterization of Leishmania donovani secretory peroxidase: delineating its role in NRAMP1 regulationAntigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.In silico predicted epitopes from the COOH-terminal extension of cysteine proteinase B inducing distinct immune responses during Leishmania (Leishmania) amazonensis experimental murine infection.Regulation of PKC mediated signaling by calcium during visceral leishmaniasis.A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.Leishmania mexicana Gp63 cDNA Using Gene Gun Induced Higher Immunity to L. mexicana Infection Compared to Soluble Leishmania Antigen in BALB/CLive Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in miceImmunogenicity of MHC Class I Peptides Derived from Leishmania mexicana Gp63 in HLA-A2.1 Transgenic (HHDII) and BALB/C Mouse ModelsSuccessful Therapy of Murine Visceral Leishmaniasis with Astrakurkurone, a Triterpene Isolated from the Mushroom Astraeus hygrometricus, Involves the Induction of Protective Cell-Mediated Immunity and TLR9Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani.Mechanisms of immune evasion in leishmaniasisClinical and Immunological Analysis of Cutaneous Leishmaniasis before and after Different Treatments.Does Leishmaniasis disease alter the parenchyma and protein expression in salivary glands?In vivo/In vitro immune responses to L. major isolates from patients with no clinical response to Glucantime.Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.Eosinophils and mast cells in leishmaniasis.Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.Role of chemokines in regulation of immunity against leishmaniasis.The role of P2 receptors in controlling infections by intracellular pathogens.Comparison of Th1 and Th2 responses in non-healing and healing patients with cutaneous leishmaniasis.Attenuated Leishmania induce pro-inflammatory mediators and influence leishmanicidal activity by p38 MAPK dependent phagosome maturation in Leishmania donovani co-infected macrophages.A comparison of serum selenium, zinc and copper level in visceral and cutaneous leishmaniasis.Clinical and laboratory profiles of patients with early spontaneous healing in cutaneous localized leishmaniasis: a historical cohort study.The Anti-leishmanial Efficacy of Artemisia dracunculus Ethanolic Extract in Vitro and Its Effects on IFN-γ and IL-4 ResponseHistopathological analysis of initial cellular response in TLR-2 deficient mice experimentally infected by Leishmania (L.) amazonensis.The Binomial Parasite-Host Immunity in the Healing Process and in Reactivation of Human Tegumentary Leishmaniasis.
P2860
Q27318412-77431A67-2E9C-4C9B-BA0E-47DD2A4A19B4Q28480551-93739A2E-26AE-42E0-8E34-8E2BFCD354BBQ28538886-069E183E-B284-4C05-8421-632B7A517DE6Q28540810-81318143-897B-4BBF-88A1-E31151B77A41Q28552919-28DBFBC8-ABBC-491B-A085-62185A3303BCQ30940594-BD890685-238E-4C58-8CB9-751E95D1567FQ33858274-6CD9A6CE-D4B8-40E1-8895-51F3B4238FDFQ34020450-305BD4B2-4244-4A8E-A654-31E91A73E241Q34292614-D1D52ED0-436B-4E7C-A0E0-C4601F87584CQ34344080-9BA276F1-C521-4DC5-B226-D381B4BBEFD4Q34551387-3BE93FF6-A856-4716-8BB8-9D0B27F2223AQ34662190-F5BEADEF-CDE9-403E-9F41-170A9CCDDA41Q35198722-CF043BCF-AC74-4C4F-8291-F89041AB2649Q35346892-A40937B5-C640-4497-BCFA-2C54958AFC5FQ35687444-0E5B991B-D638-4605-8C47-92BEB10B65F9Q35758166-116DD978-7072-4D5F-860D-AC233136E52FQ36118527-7D55D529-2DD8-4FC4-827A-87262EDCBF42Q36379560-BEC5F720-7957-44B4-BA05-6E8A613EFDC9Q36509894-ADF02D77-85B8-4173-953B-E6FF205078E3Q36888107-8BE52DE4-35D7-4B4B-B782-69381620D929Q36951476-D48C6D90-E157-44D5-9FC9-7F876DC4570BQ36969164-CBF598DE-CBBF-472F-8A9E-32B72C446A0CQ36970088-86DE7080-4F2F-4AA4-9C24-203946298EFBQ37071600-EAD2E4BE-D71A-4FC9-85D8-FBBD9767A4DFQ37157818-18862767-3177-4576-B3B5-EA99338E3CC9Q37220949-DF744DB9-D1D3-4C07-9FDD-10DB96E5150DQ37409824-58BB38D4-B8CA-4309-96F2-9085BA3A5D89Q37434214-5D0BC7EA-0519-4F31-B056-04DB463E6962Q37703644-EA6D4313-7929-48A4-9D48-24C709F0218AQ37857679-7DC46F53-C619-42CA-8BEB-08E159A6FB55Q38533597-BA8B676E-4A10-4556-BBB7-AAA8E7FCEB36Q38688691-66A61CBD-1E80-4B06-89A8-EDA097E9D8CDQ39000369-66688D85-17FC-4D50-9D30-5DDF13B62CBDQ41336329-4257B5FC-DA16-41E6-8572-0A1F8DB896A7Q42288230-86E63504-E355-4B8C-867F-74D90D72B049Q43920033-DA37C980-4FEA-4FBE-A6F6-9F8B1FFD2139Q55408705-EFDBE897-B22A-47E4-ADC7-895E4ED4652E
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Immune response to Leishmania infection.
@ast
Immune response to Leishmania infection.
@en
Immune response to Leishmania infection.
@nl
type
label
Immune response to Leishmania infection.
@ast
Immune response to Leishmania infection.
@en
Immune response to Leishmania infection.
@nl
prefLabel
Immune response to Leishmania infection.
@ast
Immune response to Leishmania infection.
@en
Immune response to Leishmania infection.
@nl
P2093
P1476
Immune response to Leishmania infection.
@en
P2093
Amit Awasthi
Bhaskar Saha
Ram Kumar Mathur
P304
P407
P577
2004-06-01T00:00:00Z